ImmunityBio
IBRX

$5.61

3.1%

Market Cap: 3.88B

About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Employees: 628

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

94% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 17

24% more capital invested

Capital invested by funds: $288M [Q4 2023] → $355M (+$67.8M) [Q1 2024]

19% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 42

11% more funds holding

Funds holding: 144 [Q4 2023] → 160 (+16) [Q1 2024]

1.23% more ownership

Funds ownership: 8.58% [Q4 2023] → 9.81% (+1.23%) [Q1 2024]

9% more call options, than puts

Call options by funds: $26.4M | Put options by funds: $24.4M

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2023] → 0 (-1) [Q1 2024]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$5

11%

downside

Avg. target

$5.50

2%

downside

High target

$6

7%

upside

2 analyst ratings

0 positive

0%

2 neutral

100%

0 negative

0%

Piper Sandler Joseph Catanzaro	7%upside $6	Neutral Maintained	29 Apr 2024
Piper Sandler Joseph Catanzaro	11%downside $5	Neutral Maintained	25 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about IBRX published over the past 30 days

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

NEW YORK , July 25, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of ImmunityBio, Inc. (NASDAQ: IBRX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm

7 Biotech Stocks to Keep on Your Clinical Radar

Initially, I had every intention to write a cookie-cutter assessment of intriguing biotech stocks; that is, I wanted to say that enterprises within this specialized healthcare field will always be relevant as humans leverage advanced innovations to address vexing conditions and diseases. That remains true.

7 Biotech Stocks to Keep on Your Clinical Radar

3 Top Cancer Treatment Stocks to Buy Now

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.

3 Top Cancer Treatment Stocks to Buy Now

Zacks Investment Research

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio (IBRX) rises 17% in the past week as it announces insurance coverage as well as the treatment of the first patients with its newly approved bladder cancer immunotherapy, Anktiva.

ImmunityBio (IBRX) Gains 17% in the Past Week: Here's Why

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

IBRX has a short interest % of the float of 33%, superior to GME at 21%. Investors should keep an eye on it for short squeeze-fueled volatility. IBRX has positive catalysts on the horizon, such as the commercialization of Anktiva for bladder cancer and the FDA review of Anktiva for lung cancer. IBRX has an overleveraged balance sheet, but the billionaire "face" of the company, Patrick Soon-Shiong, will ensure it remains solvent. Any capital raises from him likely won't increase the float.

ImmunityBio: Positive Near-Term Catalysts Create Strong Short Squeeze Potential

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the initial treatment of multiple patients in the United States to receive therapy with ANKTIVA® (nogapendekin alfa inbakicept-pmln), ImmunityBio's recently approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ. ANKTIVA was approved by the U.S. Food and Drug Administration (FDA) on April 22, 2024 for the treatment of patients with B.

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions

A short-squeeze stocks to buy are something investors need to watch out for. If investors believe that a stock's price will fall within a certain time frame, they will enter a short position.

3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions

These 5 stocks are potential short-squeeze candidates

In recent weeks, extreme volatility in specific stocks has resurged following the return of popular trader Keith Gill, also known as Roaring Kitty, to social media. After a nearly four-year hiatus, Gill disclosed a sizable stake in GameStop (NYSE: GME), reigniting interest in the stock.

These 5 stocks are potential short-squeeze candidates

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockholders of record at the close of business on April 17, 2024 are entitled to vote at and participate in the Annual Meeting. Richard Adcock, the Company's Chief Executive Off.

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

ImmunityBio: Anktiva's Launch Demands A Reassessment

ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distribution channels, and sufficient inventory. Analyst projections suggest significant growth for ImmunityBio, with the potential for Anktiva to become a blockbuster drug and drive the company's revenue in the coming years.

ImmunityBio: Anktiva's Launch Demands A Reassessment

See News Rankings